The result of the antibacterial activity are encouraging as ethanol and petroleum ether extracts exhibited antibacterial properties against 4 tested bacteria out of 5 (Table 3). These two extracts showed antimicrobial activity against B. subtilis, S. aureus, P. vulgaris and E. coli with zones of inhibition ranging from 16 to 20 mm. P. aeruginosa was found to be resistant against the plant extracts. However the extraction method did effect the antibacterial activity of the plant extracts; extracts prepared in methanol, chloroform and distilled water did not show any inhibitory activity against all the test organisms. The observed difference in antibacterial activity with respect

to extraction methods might be attributed BGB324 mouse Alisertib cost to incomplete leaching of the active substances at ambient temperature and loss of active components during boiling. The MIC test of the ethanolic and petroleum ether extract of P. aquilinum against bacterial pathogens

– B. subtilis and S. aureus were observed as 1 mg/ml. For E. coli and P. vulgaris it was found to be 0.8 mg/ml. The different bacterial strains responded to standard antibiotics streptomycin in a variable manner, resulting in zones of inhibition ranges from 7 to 24 mm. Present study revealed that extracts of the plant were better/equally effective against tested organisms except P. vulgaris as compared to streptomycin. In conclusion, leaves of the plant exhibited certain important phytochemicals, antioxidant and broad-spectrum antibacterial activity in significant amount. This plant have been in use for years to treat various ailments. Natural antioxidants of plant origin have greater application

and they can also be used as nutraceuticals and phytoceuticals as they have significant impact on the status of human health and disease prevention.10 The inhibitory activities of the extracts live up to their potential in the treatment of bacterial induced ailments or diseased conditions, in line with the traditional use of plant extracts. This investigation thus provides a scientific basis for the use of the plant extracts in home-made remedies and their potential use in the treatment of microbial-induced ailments. Further studies may lead to their use as safe alternatives to synthetic antimicrobial drugs. Detail work by using different approaches will be the the aim of further investigation. All authors have none to declare. Authors are thankful to the Dibrugarh University, Assam, India for providing necessary facilities. “
“Coronary heart disease (CHD) or coronary artery disease (CAD) is a vascular disease caused by the blockage of the arteries due to the formation of plaques made up of triglycerides.1 The plaques are composed of fats, carbohydrates, calcium, cellular wastes and fibrin. The gradual deposition of such materials over the inner wall of the arteries causes the formation of the plaque.

2). Lymphocytes from immunised pigs in experiment 1 were collected at various times post-immunisation and IFN-γ ELISPOT and proliferation assays were performed with OURT88/3 or Benin 97/1 as antigen. In all 3 pigs, the numbers of ASFV specific IFN-γ producing cells was rapidly increased after the OURT88/3 inoculation and further increased after the OURT88/1 boost. Both OURT88/3 and Benin 97/1 isolates stimulated lymphocytes from immunised pigs to an approximately equal amount (Fig. 4A–C). Low levels of proliferation were detected in all pigs

at 1 or 2 weeks post-OURT88/3 inoculation, but the amount of proliferation was dramatically increased after the OURT88/1 boost (Fig. 4D–F). In two of the pigs (Fig. 4D and E) levels of T cell proliferative responses dropped following OSI-906 solubility dmso challenge with Benin 97/1 isolate and in the other pig levels continued to rise (Fig. 4F). At the termination of the experiment, lymphocytes from these pigs were tested for cross-reactivity Palbociclib purchase stimulated with various ASFV isolates by IFN-γ ELISPOT assays (Fig. 5A). Immune lymphocytes from all 3 pigs responded similarly to OURT88/3, OURT88/1 and Benin 97/1. Lymphocytes from two pigs (VR89, VR90) also responded well to genotype 1 isolate Malta 78 and genotype X isolate Uganda 1965 and lymphocytes from pig VR90 also responded well to genotype I isolate Lisbon 57. Lymphocytes from pig VR92 responded less well to Malta 78, Uganda 1965 and Lisbon 57 and those

from pig VR89 also showed a reduced response to Lisbon 57. No cross-reactivity was observed Megestrol Acetate to genotype VIII isolate Malawi Lil 20/1. In the second experiment (Fig. 5B), lymphocytes were collected from pigs just prior to challenge. Lymphocytes from 2 of the immunised pigs (1829, 1837) showed a much stronger response in IFN-γ ELISPOT assays against OURT88/1 and

Benin 97/1 than the other 3 immunised pigs (1809, 1811, 1844). Interestingly, 2 of the pigs from which lymphocytes responded least (1811, 1844) in IFN-γ ELISPOT assays (Fig. 5B) were those which were not protected against Benin 97/1 challenge (Fig. 3C and D). No response was observed in IFN-γ ELISPOT assays when lymphocytes from non-immune pigs 1806, 1816, 1825 (Fig. 5B) were stimulated with ASFV, confirming the specificity of the assay. In the third experiment IFN-γ ELISPOT assay was carried out using lymphocytes collected prior to challenge and the results were too high to be read accurately by the ELISPOT reader (data not shown). This indicates that strong T cell immunity was induced in all pigs before the challenge. A competitive ELISA based on the p72 major capsid protein was used to measure development of anti-ASFV specific antibodies. The results from analysis of sera collected in experiment 2 and 3 are shown in Fig. 6. An antibody response developed in all pigs immunised with OURT88/3 followed by OURT88/1 boost, except pig 76 from experiment 3 in which antibody against p72 was not detected prior to boost (Fig. 6C).

asoca and may be explored for probable medicinal properties. In conclusion, present study indicates

that the flower and bark of S. asoca can be considered as a good source of gallic acid and ellagic acid. This information can also be used for authentication and quality evaluation of commercial samples. This is a continuation of our previous work where we had reported the presence of gallic acid in leaves that is quantified in the present study. The results provide an encouraging suggestion for the use of S. asoca leaves as an alternative source of gallic acid throughout the year in the absence AT13387 price of flowering season. Moreover, we suggest using the superficial layer of the bark (which has a good antioxidant property) without harming the plant as a whole, thus stressing on the need for biodiversity conservation of such an important medicinal plant species. All authors have none to declare. The authors acknowledge Ramakrishna Mission

Quality Testing Laboratory (QTL), Vivekananda University, Narendrapur, for providing research facilities. The authors are grateful to Dr. Chhanda Mandal for her help and suggestions. Authors thank the anonymous reviewers for their valuable comments and suggestions to improve our manuscript. “
“Medicinal plants are known potential source of many phenolic compounds and antioxidants. Among these, polyphenols in particular, have been recognized for antioxidant activity and many other health benefits.1 Phenolic and flavonoids, as natural antioxidants BMS-354825 ic50 and free radical scavengers, have involved substantial interest due to their importance in food and pharmacological industry.2 Factors, such as geographic location, age of the plant, season, associated microflora, Oxalosuccinic acid nutritional status, and environmental stress are known to influence the secondary metabolite profile of a particular plant species. Seasonal variation in trees, for example from dormant to active phase, brings progressive changes in traits like production

of phytochemicals.3 Besides, optimization of methods with respect to solvent system is important for determination or extraction of the phytochemicals from any plant species. Ginkgo biloba L. (family Ginkgoaceae), commonly known as living fossil, harbors many beneficial medicinal properties. Traditionally, it has been used on an extensive basis, either as food or medicinal component, almost all over the world. The leaf extract of ginkgo contains pharmaceutically imperative flavonoids, glycosides and ginkgolides which expand blood flow, act as antioxidant and mainly used as memory enhancer and anti-vertigo. 4 The present study is focused on the evaluation of phytochemicals and antioxidants in leaf extracts of ginkgo along with the factorial analysis among locations × seasons, seasons × solvents and locations × solvents.

Ratings were recorded on a Likert-type scale from 1 (participant refused to co-operate with the intervention) to 5 (excellent selleck products co-operation). The quality of each intervention was rated by the participant. Ratings were recorded on a Likert-type scale from 1 (poor) to 5 (excellent). The ratings of treatment quality were made at the end of the 40-min rest period for each intervention. Participant satisfaction with each intervention was rated by participants on a visual analogue scale from 0 (not satisfied at all) to 100 (fully satisfied). The ratings of satisfaction were made at the end

of the 40-min rest period for each intervention. Any adverse changes in a participant’s clinical status were noted as an adverse event. Non-invasive pulse oximetry was used throughout each intervention to monitor for oxyhaemoglobin desaturation.

We calculated the sample size based on the primary outcome. For the smallest worthwhile effect of one intervention versus another, we nominated a 1.5 g difference Vorinostat in vivo in the wet weight of expectorated sputum produced. We anticipated a standard deviation of the difference between the two values for the same patient at 2.8 g, based on data reported by Bilton et al (1992). With an alpha risk of 5% and a study power of 80%, a total of 30 patients were required. To allow for 10% loss to follow-up, this sample was increased to 34 participants. The characteristics of the participants were described using means and standard deviations for continuous variables and using numbers and percentages for categorical variables. An analysis of variance, which took period and sequence effects into account, was used to estimate the effect of the intervention on sputum weight and FEV1. In the absence of period and sequence effects, a paired t-test was calculated. Co-operation and perceived treatment quality were analysed as the relative risk of a rating of good to excellent. Adverse events were also analysed using relative risk. 3-mercaptopyruvate sulfurtransferase A

mixed-effect Tobit model was used to analyse the effect of the intervention on satisfaction while taking a ceiling effect into account. Fifty-five patients were assessed for eligibility, of whom 34 underwent randomisation (Figure 1). Among the 10 patients who refused to participate, 4 stated that they did not enjoy sport and 6 stated that they did not like spirometry. The baseline characteristics of the participants who completed the study are presented in Table 1 The two groups of participants were comparable at the start of the intervention arms in terms of pulmonary function, nutritional status and therapeutic requirements (Table 2 and the first two columns of data in Table 3). There was also no statistically significant difference in FEV1 values between the start of the first and second intervention arms (p = 0.6).

5 ml of molten 0.6% LB agar. The surface of the plates were overlaid with the soft agar and allowed to set. Luria Bertani (LB) broth (1.0 ml) containing 0.5% NaCl was added to the vial containing freeze-dried phage and 0.1 ml of the rehydrated phage was learn more spotted onto the overlay. The plate was tilted to spread the rehydrated phage over as much of the surface as possible. This was allowed

to dry and incubated at 37 °C overnight. After 24 h incubation, the soft agar was scraped from the surface of the agar plates using a sterile cell scraper. The soft agar was centrifuged at 1000 rpm for 25 min to sediment the cellular debris and agar. The supernatant was passed through a 0.22 μm Millipore filter and the filtrate was stored at 4–8 °C. The double layer plaque assay method was adapted from a method devised by Adams (1959). An actively growing broth culture of E. coli 11303 was prepared 18–24 h before performing the plaque assay. Plates of 1.2% LB agar were pre-warmed Pomalidomide purchase in an incubator at 37 °C. Plates were prepared as previously described. Serial dilutions of the samples obtained from the in vitro release study were prepared from 10−1 to 10−8. The agar overlay was prepared by adding 60 μl of the E. coli innoculum into 3 ml of 0.6% top agar and poured immediately onto the 1.2% agar plates and agitated to ensure even distribution. Samples of each serial dilution (20 μl) were spotted onto the overlay, with 4–5 dilutions per plate.

Each sample was spotted in triplicate

to ensure reproducibility. The plates were incubated at 37 °C overnight. Plaques were subsequently enumerated on plates at each dilution. Plaques appear as defined, circular zones of clearance within the bacterial these lawn, due to bacteriophage-mediated bacterial cell lysis. The concentration of bacteriophage present in each sample was calculated from the dilution in which plaques were most countable, and using the following equation: equation(1) Number of plaques×dilution factor×50=Concentration in PFU/mlNumber of plaques×dilution factor×50=Concentration in PFU/mlwhere 20 μl is plated, ×50 to calculate PFU/ml. An average of the three results was taken as the phage concentration. The delivery of a stock solution (5 × 108 PFU/ml) of T4 bacteriophage across neonatal porcine skin, using the hollow MN system was carried out using Franz diffusion cells (FDC-400 flat flange, 15 mm orifice diameter, mounted on an FDCD diffusion drive console providing synchronous stirring at 600 rpm and thermostated at 37 ± 1 °C, Crown Glass Co. Inc., Sommerville, NJ, USA). The orifice diameter in the receptor compartment was 15 mm. No donor compartment was used, to allow ease of use of the hollow MN device. The receptor compartment volume was calculated to be 12 ml. PBS pH 7.4 (11 ml) was accurately dispensed into the receptor compartment using a 5 ml Pipetteman®, assuming that the full 1000 μl would be delivered via the hollow MN device. The PBS was degassed prior to use by sonication.

Après mon exposé Eccles m’a demandé où j’avais appris ça. Je lui répondis “nulle part, et j’ai tout fait moi-même”. Eccles a été très impressionné et m’a invité à venir à Canberra, tous frais payés. De retour à Kiev, j’ai préparé tous les documents nécessaires et les ai fait parvenir au service des relations internationales. Des semaines et des mois passèrent sans réponse. Je ne fis aucune démarche pour accélérer la décision de l’administration mais

un jour la direction reçut un appel téléphonique international, see more ce qui était très rare à l’époque. C’était Eccles, qui voulait savoir pourquoi je n’étais pas venu à Canberra. Je lui répondis que la décision ne dépendait pas de moi. Eccles a très bien compris et a dit: “Très bien, je vais envoyer un télégramme à Khrouchtchev”. www.selleckchem.com/products/r428.html Bien sûr, cette communication téléphonique ne resta pas confidentielle, et suscita un grand émoi

dans l’institut. Je ne sais pas si Eccles a vraiment contacté N.S. Khrouchtchev mais, quoiqu’il en soit, je reçus tous les documents quelques jours après. C’est ainsi que je me suis rendu en Australie où j’ai travaillé pendant six mois». Lors de cette courte période P.G. Kostyuk noua de sérieuses relations avec un grand nombre de scientifiques de divers pays et ne publia pas moins de 5 articles scientifiques. L’hypothèse de Eccles-Kostyuk-Schmidt, formulée à la fin des années 60, sur l’existence de 2 systèmes de régulation présynaptique du signal nerveux est entrée dans tous les manuels de neurophysiologie et fut étudiée dans toutes les universités (Fig. 4). C’est à cette époque que P.G. Kostyuk a commencé à publier dans why des journaux internationaux. En 1966, il fut nommé directeur de l’Institut de Physiologie Bogomolets qu’il dirigera pendant près de 45 ans. Sous sa direction, cet institut est devenu l’un des meilleurs centres de recherche en neurosciences non seulement en URSS mais aussi au niveau international.

Des chercheurs remarquables comme V. Skok, M. Shuba et O. Krishtal en sont issus. En 1979 grâce à l’énergie et l’autorité de Platon Kostyuk de nouveaux bâtiments ont été construits et équipés d’instruments modernes. Beaucoup de conférences, de congrès et d’enseignements scientifiques s’y sont déroulés, attirant de nombreux chercheurs du monde entier. Des collaborations étroites ont été nouées avec la plupart des Universités et des Instituts les plus prestigieux d’Europe comme des Etats-Unis d’Amérique ou du Japon. Des découvertes importantes y ont été réalisées. L’enregistrement des courants transmembranaires de cellules au contenu intracellulaire modifié par la méthode de perfusion intracellulaire, qu’il a mise au point, a permis de caractériser de nouveaux types de canaux ioniques.

N Engl J Med 368: 1675–1684. [Prepared by Kåre B Hagen and Margreth Grotle, CAP Editors.] Question: Does arthroscopic partial meniscectomy and postoperative physiotherapy result in better functional outcomes than standardised physiotherapy (PT) alone for

symptomatic patients with a meniscal tear and knee osteoarthritis Cabozantinib molecular weight (OA)? Design: A randomised, controlled trial in a 1:1 ratio with concealed allocation. Setting: Seven US tertiary referral centres. Participants: Men and women, aged 45+ years with a meniscal tear, mild to moderate OA, symptoms for at least four weeks, managed with medications, activity limitations, or PT. Exclusion criteria comprised having a chronically locked knee, severe OA (Kellgren-Lawrence Grade 4), inflammatory arthritis, or prior surgery to the affected knee. Randomisation of 351 participants allocated 171 to arthroscopic LY2835219 ic50 partial menisectomy followed by PT and 177 to PT alone. Interventions: Both groups received a similar PT program. The PT program was based on land-based, individualised physiotherapy with progressive home exercises. A phased structured

program was designed to decrease inflammation, restore active joint range and neuromuscular re-education of quadriceps (Phase 1), restore muscle strength and endurance, re-establish full and pain-free active joint range, gradual return to functional activities, and minimise gait deviations (Phase 2), and enhance muscle strength and endurance, and return to sports/functional activities (Phase 3). It was recommended that the patient attend PT sessions once or twice weekly for six weeks and perform exercises at home. In addition, the surgery group had arthroscopic partial meniscectomy performed by trimming the damaged meniscus back to a stable rim followed by postoperative PT. Outcome measures: The primary outcome was change in the physicalfunction scale of the Western Ontario and McMaster Universities (WOMAC)

questionnaire from baseline to six months follow up. Secondary outcomes included the pain score on the Knee Injury and Osteoarthritis Outcome Scale (KOOS) and the physical-functioning Tryptophan synthase scale of the 36-Item Short-Form Health Survey (SF-36). Results: In total, 330 patients completed the six month follow-up. There was no difference between the groups in change in the WOMAC physical-function score (mean difference 2.4 points, 95% CI −1.8 to 6.5). There were also no significant differences between the groups in the KOOS pain score, SF-36 physical functioning, or frequencies of adverse events. At six months, 51 (30%) active participants in the study who were assigned to PT alone had undergone surgery, and 9 patients assigned to surgery (6%) had not undergone surgery.

To decrease data entry for the clinic staff date of birth and gender were entered on-line by survey respondents. The survey provided simple check-boxes and free text boxes as required. The 2013 Vaxtracker online survey was simplified by adding a screening question so that the 11 symptom questions

only appeared if the parent or carer clicked “yes” to the question: “Did (child’s Selleckchem Carfilzomib first name) experience and kind of reaction, illness or discomfort after the vaccination?” An answer of “yes” to any of the symptom questions in the first online survey activated a drop down box with additional questions regarding severity, whether medical advice was sought and duration of the event. The 11 symptoms explored in the 2012 and

2013 pilot studies were: reaction at injection site, fatigue, influenza-like illness, muscle aches, headaches, joint pain, fever, PD173074 mouse lymph node swelling, weakness, seizures and “other” symptoms. Recruitment and adverse events were reviewed by surveillance staff to detect any signal of adverse events. Data on recruitment and adverse events were available through the dedicated secure website and was downloaded twice weekly to monitor adverse events, recruitment by each clinic and prepare weekly reports. An automated email alert to the Vaxtracker team was generated when a seizure or hospitalisation was reported so that review could occur rapidly. Survey completion rates were calculated as the number of participants who completed the survey divided by the total participants due to have completed the survey. Weekly reports were shared with health departments at State and National level and a final report with the Therapeutic Goods Administration (TGA). All serious adverse events including high fever, seizures, unresolved systemic symptoms or hospitalisation were whatever followed up by telephone by a registered nurse and reviewed with a public health physician and if required notified to NSW Health through usual AEFI notification channels. Adverse events were described according to demographic characteristics of the participants, previous vaccine history and the brand of IIV administered.

Factors associated with adverse events were investigated by comparing participants who experienced an adverse event with those who did not experience an adverse event by the following factors; age (t test of mean age), gender and first year of IIV administration (comparison of proportions using Pearsons Chi-squared test). The analysis controlled for gender, age by year and whether first time influenza vaccine was received in the current season. There is a Vaxtracker Standing Operating Procedure for validating reports that are questionable with attending clinicians. Surveillance of AEFIs is conducted in NSW under the NSW Public Health Act, therefore ethical review was not required for this enhancement to existing surveillance.

Currently, lentogenic strains are widely used as live NDV vaccines for poultry throughout the world. NDV has several properties that are useful

in a vaccine vector in non-avian hosts. NDV is attenuated in non-human primates, and likely in other non-avian species, due to a natural host range restriction [22] and [23]. NDV is antigenically distinct from common animal and human pathogens, and thus would not be affected by preexisting immunity in humans and animals. NDV can infect efficiently via the intranasal (IN) route and has been shown to induce humoral and cellular immune responses both at the mucosal and systemic levels selleck chemicals in murine and nonhuman primate models. NDV was used to express protective antigens of simian immunodeficiency virus, respiratory syncytial virus, H5N1 avian influenza virus and human immunodeficiency virus in mice; human parainfluenza virus type 3, severe acute respiratory syndrome associated coronavirus and H5N1 avian influenza virus in monkeys [22], [23], [24], [25], [26], [27] and [28]. However, NDV has not been explored as a viral vector for pathogens of cattle. There are many diseases of cattle for which effective vaccines are not available. Recently we evaluated the replication

and immunogenicity of NDV in calves and showed that NDV was highly attenuated due to host range check details restriction and yet induced virus-specific humoral and mucosal antibody responses in this unnatural host [29]. In the present study, we examined the widely used avirulent

NDV vaccine strain LaSota as a topical respiratory vaccine vector to deliver the gD of BHV-1 as a test foreign antigen. Two different recombinant NDVs, one expressing the native gD and the other expressing a chimeric version of the gD, were constructed. These NDV vectored vaccines were evaluated for replication, pathogenicity for birds, immunogenicity and protection against BHV-1 following IN and intratracheal (IT) immunization of calves. Our results indicated that a single IN administration of recombinant NDVs expressing BHV-1 gD resulted in the induction of mucosal and systemic antibody responses against Adenylyl cyclase BHV-1 and provided partial protection against IN challenge with a virulent BHV-1. The NDV vectored vaccines were safe and attenuated in cattle, suggesting that NDV can be used to elicit antigen specific immune responses against other pathogens of cattle. Further our data indicated that the gD alone may not be sufficient to confer complete protection against BHV-1 challenge. Inclusion of other BHV-1 glycoproteins, namely gC and gB, along with gD may be necessary for generation of complete protection against BHV-1.

1H NMR (300 MHz,

DMSO-d6, δ ppm): 9.3 (s, 1H, OH), 7.7–8.2 (m, 8H, Ar), 8.1 (s, 1H, CH), 5.05 (s, 2H, CH2), 3.78 (s, 3H, OCH3). Anal. calcd. for C19H15NO5S: C 61.78, H 4.09, N 3.79. Found: C 61.88, H 3.97, N 3.66. 5-(4-Hydroxy-3-methoxybenzylidene)-N-[2-(4-methoxyphenyl) -2-oxoethyl]-1,3-thiazolidine-2,4-dione (3g): Pale yellow solid, IR (KBr, cm−1): 3012, 1732, 1638, 1465, 1408, 1194, 1189, 634. 1H NMR (300 MHz, DMSO-d6, δ ppm): 9.4 (s, 1H, OH), 7.5–8.1 LY2157299 cost (m, 8H, Ar), 7.9 (s, 1H, CH), 4.9 (s, 2H, CH2), 3.54 (s, 6H, OCH3). Anal. calcd. for C20H17NO6S: C 60.14, H 4.29, N 3.51.

Found: C 60.02, H 4.17, N 3.44. 5-(3,4-Dimethoxybenzylidene)-N-[2-(4-methoxyphenyl)-2-oxoethyl]-1,3-thiazolidine-2,4-dione (3h): Pale yellow crystals, IR (KBr, cm−1): 3031, 1775, 1656, 1451, 1202, 1156, 645. 1H NMR (300 MHz, DMSO-d6, δ ppm): 7.65–8.2 Selleckchem BYL719 (m, 8H, Ar), 7.8 (s, 1H, CH), 5.3 (s, 2H, CH2), 3.72 (s, 9H, OCH3). Anal. calcd. for C21H19NO6S: C 61.01, H 4.63, N 3.39. Found: C 60.87, H 4.44, N 3.19. 5-(Benzylidene)-N-(4-nitrobenzyl)-1,3-thiazolidine-2,4-dione (4a): Beige colour solid, IR (KBr, cm−1):

3113, 1737, 1660, 1524, 1417, 692. 1H NMR (300 MHz, DMSO-d6, δ ppm): 7.2–8.1 (m, 9H, Ar), 8.04 (s, 1H, CH), 5.1 (s, 2H, CH2). Anal. calcd. for C17H12N2O4S: C 59.99, H 3.55, N 8.23. Found: C 59.78, H 3.46, N 8.11. 5-(4-Chlorobenzylidene)-N-(4-nitrobenzyl)-1,3-thiazolidine-2,4-dione (4b): Pale yellow crystals, IR (KBr, cm−1): 3034, 1735, 1680, 1545, 1282, 1401, 756, 697. 1H NMR (300 MHz, DMSO-d6, δ ppm): 7.5–8.3 (m, 8H, Ar), 7.98 (s, 1H, CH), 4.95 (s, 2H, CH2). MS (ESI, through m/z):374 (M+). Anal. calcd. for C17H11ClN2O4S: C 54.48, H 2.96, N 7.47, O 17.08. Found: C 54.23, H 2.65, N 7.22, O 17.01. N-(4-Nitrobenzyl)-5-(4-nitrobenzylidene)-1,3-thiazolidine-2,4-dione (4c): Half-white crystals, IR (KBr, cm−1): 3028, 1698, 1632, 1538, 1505, 1431, 638. 1H NMR (300 MHz, DMSO-d6, δ ppm): 7.1–8.1 (m, 8H, Ar), 7.8 (s, 1H, CH), 4.85 (s, 2H, CH2). Anal. calcd. for C17H11N3O6S: C 52.99, H 2.88, N 10.9. Found: C 52.79, H 2.75, N 10.76. 5-(4-Methoxybenzylidene)-N-(4-nitrobenzyl)-1,3-thiazolidine-2,4-dione (4d): Half-white solid, IR (KBr, cm−1): 2841, 1737, 1683, 1506, 1407, 1184, 702. 1H NMR (300 MHz, DMSO-d6,δ ppm): 7.08–8.25 (m, 8H, Ar), 7.9 (s, 1H, CH), 4.95 (s, 2H, CH2), 3.81 (s, 3H, OCH3). MS (ESI, m/z): 370 (M+). Anal. calcd. for C18H14N2O5S: C 58.37, H 3.81, N 7.56. Found: C 58.62, H 3.78, N 7.24.